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Abstract 
   Background: 
             Non-alcoholic fatty liver disease [NAFLD] is a chronic live disease 
that is attracting increasing significance. 
It is aclinicopathological syndrome that has been described in obese, 
diabetic, females who denied alcohol use but in whom the hepatic histology 
was consistent with alcoholic hepatitis. 
              Type 2 diabetes is a major component of the metabolic syndrome 
(syndrome x), which is characterized by: type 2 diabetes, obesity, 
hyperinsulinaemia and peripheral insulin resistance, hypertriglyceridemia 
and hypertension. Most of these components are implicated as a cause 
and/or association with fatty infiltration of the liver. 
Objective: 
                 The aim of this study is to determined the prevalence of fatty liver 
disease in Sudanese patients with type II diabetes. 
Methods: 
                  This is a descriptive cross- sectional study, which included 50 
patients with type 2 diabetes for 10 years or more, who came from different 
area in Sudan, were screened by ultrasonography for the presence of fatty 
liver at The National Center for Gastrointestinal and Liver disease. 
                  Data were collected using a well-designed questionnaire and 
results were analyzed by using SPSS computer system. 
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Results: 
                   This study included 50 patients with type 2 diabetes for 10 years 
or more, 38 patients were found to have fatty liver  on u/s with male to 
female ratio (1:1.7). 
  The main presenting symptoms in patients with FLD  were right upper 
abdominal pain (52%), fatigability (38%), hepatomegaly (6%) and jaundice 
in (1%). Central obesity was clinically detected by waist- hip-ratio in (53%) 
of female and (13%) of males patients.  Parameter of  uncontrolled diabetes 
such as elevated fasting blood glucose was detected in (74%) of patients, 
elevated Hb A1C (84%) ,and raised serum triglyceride in (63%) of patients 
was found in the study group with FLD. Liver profile, prothrombine time 
and screening for HBV,HCV all were normal and negative respectively. 
Conclusion: 
                 Fatty liver disease as determined by ultrasound is common in 
Sudanese patients type II diabetics patients and this was associated with poor 
glycemic control, hyperlipidemia and hypertension.   
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  ﻣﻠﺨﺺ اﻻﻃﺮوﺣﺔ
   
  :    ﻣﻘﺪﻣﺔ
           ﻤﺭﺽ ﺍﻟﻜﺒﺩ ﺍﻟﺩﻫﻨﻰ ﻫﻭ ﺍﺤﺩ ﺍﻤﺭﺍﺽ ﺍﻟﻜﺒﺩ ﺍﻟﻤﺯﻤﻨﺔ ﺍﻟﺫﻯ ﺍﺴﺘﺭﻋﻰ ﺍﻟﻜﺜﻴﺭ 
ﻭﻗﺩ ﺍﺭﺘﺒﻁ ﻭﺠﻭﺩﻩ ﺒﺎﻟﺴﻤﻨﺔ ﻭﺍﻟﻨﺴﺎﺀ ﻭﻤﺭﺽ ﺍﻟﺴﻜﺭﻯ . ﻤﻥ ﺍﻻﻨﺘﺒﺎﻩ ﻓﻰ ﺍﻻﻭﻨﺔ ﺍﻻﺨﻴﺭﺓ 
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ﺍﻟﺴﻜﺭﻯ ، ﺍﻟﺴﻤﻨﺔ، ﺍﺭﺘﻔﺎﻉ ﺍﻨﺴﻭﻟﻴﻥ ﺍﻟﺩﻡ، ﺍﻟﻤﻘﺎﻭﻤﺔ ﺍﻟﻁﺭﻓﻴﺔ ﻟﻼﻨﺴﻭﻟﻴﻥ، ﺯﻴﺎﺩﺓ : ﻋﻠﻰ 
ﺍﻟﻤﻜﻭﻨﺎﺕ ﺘﺸﺘﺭﻙ ﻭﺘﺅﺜﺭ ﻓﻲ ﺘﻜﻭﻴﻥ ﻤﺭﺽ  ﺸﺤﻭﻡ ﺍﻟﺩﻡ ﻤﻊ ﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ ﻭﻜل ﻫﺫﻩ
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INTRODUCTION AND LITERATURE REVIEW 
 
          1.1 Introduction: 
 
        Non-alcoholic fatty liver disease [NAFLD] is a chronic live disease that is 
attracting increasing significance. 
       It is aclinicopathological syndrome that has been described in obese,diabetic , 
females who denied alcohol use but in whom the hepatic histology was consistent 
with alcoholic hepatitis. 
      Non-alcoholic fatty liver disease [NAFLD] can be a consequence of many 
diseases including, type 2 diabetes, metabolic disorders, gastrointestinal bypass 
surgery, nutritional disorders, HCV and drugs. 
       Type 2 diabetes is a major component of the metabolic syndrome (syndrome 
x), which is characterized by: type 2 diabetes, obesity, hyperinsulinaemia and 
peripheral insulin resistance, hypertriglyceridemia and hypertension. Most of these 
components are implicated as a cause and/or association with fatty infiltration of 
the liver. 
 
1.2 Literature Review : 
 
1.2.1 Definition: 
         Diabetes mellitus is a clinical syndrome of chronic hyperglycaemia and 
relative insulin deficiency, resistance, or both, It affects more than 120 million 
people worldwide, and it is estimated that it will affect 220 million by the year 
2020. Diabetes is usually irreversible and, although patients can have a reasonable  
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normal life style, its late complications result in reduced life expectancy and major 
health cost (1). 
 
1.2.2 Classification of diabetes: 
 
        Two main methods of classification have appeared in recent years.(2) 
 
1.2.2.1 The first classification: 
 
- Primary diabetes mellitus. 
- Secondary diabetes mellitus. 
 
      I. Primary diabetes mellitus is further   classified into types I,II,III. 
Type I & II classification attempt to assign a patho genetic mechanism, to which 
the patients will be subject all his or her life once it has started. 
The two mechanisms may not be exclusive. People can be afflicted very severely 
or mildly by either. 
          Type I diabetes is the result of an autoimmune destruction that occur at any 
age. It typically presents before 30 years, but can occur at any age. Islet-cell 
antibodies are usually found in the plasma for a period of 1-2 years after diagnosis, 
but in a minority (20%) these may persist for the remainder of the patient's life.
 Members  of this subgroup are some times called type I b .Most type I 
patients are insulin dependent. 
              Type II diabetes have variety of disease processes, which may give rise to 
the type II syndrome. Type II non- obese patients have a tendency to insulin 
resistance, alternative name maturity onset diabetes of the young (MODY), but 
obese subjects have insulin resistance and hyperinsulinaemia. 
           Type II diabetic patients may or may not need insulin in their management 
as a hypoglycemic agent. 
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             Type III appears to be confined to those born in the tropics. The 
destruction of the pancreatic Islets of langerhans in type III disease seem to be the 
result of an initial exocrine pancreatic lesion caused by multiple small calculi in the 
finer branches of the pancreatic duct, the whole process is known as tropical 
fibrocalculus disease.(3)  
     II. Secondary diabetes may be due to pancreatic diseases, gestational diabetes, 
endocrinopathies, genetic syndromes and drugs .(4) 
 
1.2.2.2 The second classification of diabetes mellitus:- 
 
     This classification applies to the metabolic state of a subject at one instant, and 
can change with time, it includes:- 
1. Insulin dependent diabetes mellitus (IDDM). 
2. Non-insulin dependent diabetes mellitus (IDDM) 
 
1.2.3 Insulin Resistance: 
 
       Hyperglycemia in typeII DM results from undefined genetic defects, the 
expression of which is modified by environmental factors  .Fasting insulin level is 
generally normal or increased in typeII DM. Yet it is relatively low if one takes 
into account the co-existing presence of hyperglycemia. As hyperglycemia 
becomes more severe, basal insulin fails to increase or decline further. 
       TypeII diabetes is characterized by marked impairment in insulin action. The 
insulin dose-response curve for augmenting glucose uptake in peripheral tissues is 
shifted to the right (decreased sensitivity), and the maximal response is reduced, 
particularly with more severe hyperglycemia. Other insulin-stimulated processes 
such as inhibition of hepatic glucose production and lipolysis also show reduced 
sensitivity to insulin. (5,6) 
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     The mechanism responsible for insulin resistance remains poorly understood, 
although insulin receptors may be reduced in some type 2 DM patients. Defects in 
more distal or (post-receptor) events play the predominant role in insulin resistance 
and whether the defects uncovered are primary or secondary to the disturbance in 
glucose metabolism is uncertain. One study have suggested a linkage between 
type2 diabetes and chronic hepatitis C virus (HCV) infection.(7).  In this study, 
transgenic mice that carry the core gene of HCV were analyzed. They found that 
these mice developed insulin resistance. An addition of a high-caloric diet led to 
the development of type 2DM by disrupting the balance between insulin resistance 
and secretion. These result indicate a direct involvement of HCV per se in the 
pathogenesis of diabetes in patients with HCV infection and provide a molecular 
basis for insulin resistance in such a condition in addition HCV is common cause 
of hepatic steatosis.(8)  
       The co-existence of obesity accentuates the severity of the resistance status. In 
particular, abdominal obesity as compared with low body or peripheral obesity is 
associated with insulin resistance and diabetes. It is now believed that 
intrabdominal visceral fat may be a key culprit. Abdominal fat cells have higher 
lipolytic rate and are more resistance to insulin than that derived from peripheral 
deposits. (2,9) 
1.2.4 Obesity:- 
        The terms overweight and obesity are frequently used interchangeably, 
although they are defined differently. 
       Body mass index (BMI) is the most practical way to evaluate the degree of 
excess weight. It is calculated from the weight and square of the height as follows:- 
BMI =body weight (in kg) /(height in meters squared). 
- overweight is defined as a BMI between 25-29.9 kg/m2 
- Obesity is defined as BMI of 30 kg/m2 or more.  
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The regional fat distribution especially abdominal (also called central adiposity, 
visceral, android or male type obesity) is associated with increased risk of 
morbidity, mortality, diabetes, hypertension, hyperlipidemia and women breast 
cancer.(10) 
   Estimation of the central adiposity is calculated from waist and hip 
circumferences as follows: 
Waist (cm)     /  Hip (cm) =Ratio      i.e. (WHR)  
A WHR of 0.95 or more, for male and 0.85 or more for female are considered to be 
at increased risk for comorbid condition including diabetes, cardiovascular disease, 
hypertension, dyslipidemia and sleep apnea. (11) 
 
1.2.5 Lipid Metabolism:- 
 
      Insulin is an important agent in lipid metabolism because it activates adipose 
tissue lipoprotein lipase (lipogenesis) and inhibits adipocyte-hormone-sensitive 
lipase ( lipolysis). Deficient insulin action has two effects on the adipose tissue: 
first, impaired degradation of both chylomicrons and  Very Low density 
lipoprotein  VLDL. Secondly through stimulation of hormone-sensitive lipase, 
leading to an increased flux of non-esterified fatty acids to the liver as a potential 
source of hepatic cell triglyceride, and of both VLDL and ketone bodies leaving 
the liver. Hence diabetics show a high triglyceride than cholesterol levels and 
accelerated arteriosclerosis. (2) 
     Diabetes mellitus, insulin resistance, obesity, dyslipidemia, hypertension are the 
components of the metabolic syndrome. (12) 
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1.2.6 Metabolic Syndrome: 
 
   It is a cluster of metabolic abnormalities that represent and increase risk of 
coronary heart disease. (12, 13). There are different nomenclatures: 
• Insulin resistance syndrome 
• Syndrome 
• REANEN Syndrome. 
• Deadly Quart let. 
The World Health Organization WHO diagnostic criteria includes:- 
BMI > 30 kg/m2  
WHR > 0.9 for male              
WHR >0.85 for female. 
Serum Triglyceride   ≥ 150 mg/dI.  
Serum HDL     ≤40 mg/dI for male 
 Serum HDL    ≤ 50 Mg/dI for female. 
BP    ≥    140/90 mm Hg. 
Diabetes or Impaired glucose tolerance. 
    It is now recognized that insulin resistance is an important aspect of NAFL (12) 
and is present even in NAFL patients who are of normal weight and have normal 
carbohydrate tolerance. Hepatic steatosis has been proposed as a feature of insulin 
resistance syndrome.(12,14,15) 
 
1.2.7 Complications of Diabetes:- 
        Diabetics are prone to a variety of complications, which are metabolic, 
vascular and non vascular. This is most common in those with highest 
concentration of blood glucose. One of those non vascular complications is fatty liver. 
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      Fatty liver is defined as accumulation of lipid in the liver exceeding 5% of the 
liver weight or visualization of more than 5% of hepatocytes containing fatty liver 
droplets on light microscopy (16) fig (17). It has been classified as alcoholic or non 
alcoholic Non-alcoholic fatty liver disease (NAFLD) is further classified into:    
- Primary, which is caused by conditions associated with insulin resistance 
syndrome. 
- Secondary NAFL caused by, metabolic disorder, nutritional disorders, viral 
hepatitis C and drugs. 
More over, diabetes mellitus has been proposed as a risk factor for both chronic 
necroinflammatroy condition that can lead to liver fibrosis, cirrhosis and 
subsequently hepatocellular carcinoma HCC. Earlier epidemiologic studies showed 
no association between DM&HCC, whereas several more recent studies indicated 
a significant association between HCC&DM.(17) 
 
1.2.7.1 Non-alcoholic Fatty Liver Disease  
 
         Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that is 
attracting increasing significance and is a recognized cause of liver related 
morbidity& mortality. (18) 
        It is common in type 2 diabetic patients,occuring in up to 75% of patient. 
Although obesity is often a confounding variable in type 2 diabetes, a number of 
studies observed that ,  the hepatic fibrosis that occurs in obese subjects was more 
prominent in obese patients with diabetes. (19) 
        It is now recognized that insulin resistance is an important aspect of NAFLD 
and is present in NAFLD patients who are of normal weight and have normal 
carbohydrate tolerance. 
In fact hepatic steatosis has been proposed as a feature of the insulin resistance 
syndrome. (20) 
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1.2.7.2 Epidemiological Feature of NAFLD: 
 
         The epidemiological impact of NAFLD is related to their prevalence and 
natural history. It is estimated that the prevalence of NAFLD is approximately 20% 
and non alcoholic steato hepatitis (NASH) 3%  in general population, however it is 
higher in certain groups such as, type 2 DM and obese patients comprising 63% 
and 39% respectively (18). Risk factors for these adverse clinical symptoms include 
patients older than the age of 45, the presence of diabetes, obesity and AST/ALT 
ratio> 1 and hepatic histology, which included: Steatosis, steatonecrosis and 
fibrosis. (18  ,21,22,23) 
       There is a direct correlation between type 2diabetes and degree of obesity and 
the prevalence and severity of NAFLD. 
Truncal obesity seem to be an important risk factor for NASH even in subjects 
with normal body mass index.(24) 
       NAFLD may affect any age group and has been described in most ethnic 
groups. Most series characterized a NAFLD patient as a middle-aged womam, but 
other have shown a significantly greater prevalence of NAFLD in males than 
females. (21) 
 
1.2.7.3 Clinical Presentation: 
 
      The majority of patients with fatty liver are asymptomatic(21) .They often 
present for evaluation of hepatomegaly or with mild abnormalities of the serum 
amino transferases or alkaline phosphatase detected in routine visits to their 
physician. However, some patients presented with symptoms of fatigue and right 
upper abdominal discomfort. Severe fatty liver can present with symptoms of 
Jaundice, abdominal pain, nausea, vomiting and tender hepatomegaly (25) . 
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1.2.7.4 Pathogenesis of NAFLD: 
 
       The primary metabolic abnormality leading to lipid accumulation in the liver, 
however, is not well understood, but it could potentially result from insulin 
resistance and alternations in the uptake, synthesis, degradation or secretory 
pathways of hepatic lipid metabolism.  Insulin resistance represents the most 
reproducible factor for the development of NAFLD. (21, 24, 26) 
      The fatty liver may be vulnerable to further injury when challenged by 
additional insulin. This has led investigators to presume that progression from 
simple, uncomplicated steatosis to    steatohepatitis to advance fibrosis results from 
two operating “hits”. (22) 
      The first is insulin resistance leading to accumulation of fat within hepatocytes, 
and the second is mostly reactive oxygen species leading to lipid peroxidation, 
cytokine production and fas ligand induction (27) . Oxidative stress and lipid  
peroxidation are key factors in the development and progression from steatosis to 
more advanced stages of liver damage. 
 
1.2.7.5 Pathology: 
 
      Histologically, there are different patterns of NAFLD: 
- Fat alone. 
- Fat plus inflammation. 
- Fat plus ballooning degeneration. 
- NASH. 
The latter is the most serious from of NAFLD. The morphological pattern of 
diabetic steatohepatitis resembles that seen in alcoholic hepatitis. However, the 
histopathological changes in diabetes tend to be periportal (situated in zone 1), 
while those in alcoholic hepatitis are predominantly pericentral(zone III) (28), which 
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are moderate to severe macrovesicular steatosis, lobular hepatitis with necrosis or 
ballooning degeneration and/ or fibrosis (18,28). In humans perisinusoidal fibrosis 
often parallels with diabetic microangiopathy    (15, 29) . 
  
1.2.7.6 Investigations: 
 
• Laboratory result abnormalities in patients with fatty liver are usually 
minimal. Most common are elevations of the serum aminotransferases, 
alkaline phosphatase or gamma glutamyl transpeptidase. Often only one 
single liver test abnormality, such as elevated alkaline phosphatase is 
detected. Less common abnormalities are elevation of direct serum 
bilirubin and decreased serum albumin. Severe fatty liver, as noted above, 
can present with Jaundice and marked abnormalities of liver tests(30)  . 
•      Imaging Study :                                                                                                                
          Ultrasound should be the first radiographic screening test ordered to 
determine if fatty liver is present. The liver will appear hyper echoic and has 
been described as a bright liver fat accumulation(31) . 
Computed tomography (CT) will also demonstrate fatty changes in patients 
with NAFLD. The liver density will appear lower than that of the spleen. 
Magnetic resonance imaging (MRI) will demonstrate fatty liver change on   
T-weight images. For most patients with NAFLD, ultrasound imaging that 
identifies fatty change of the liver is sufficient, and CT and MRI can be 
reserved for patients though to have other diseases or complication. 
      In a prospective study, 187 patients with diffuse fatty liver infiltration 
which was estimated by ultrasound tomography were investigated. In any 
case the history as well as the results of clinical investigation and labrotory. 
Findings were known to the observer. 
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Liver blind puncture were performed after a short time on an average of 
11days(32) . 
        The sonographic  fatty infiltration “of the liver could be confirmed by 
histological findings in 91.4%. While in the other cases the diagnosis is 
incorrect or incomplete respectively(32)  . 
Liver Biopsy: 
       Only in those cases, in which the sonographic diagnosis “fatty 
infiltration” is not confirmed by case history, clinical and lab finding the liver 
biopsy is to be performed(32). Although liver biopsy is the only means of 
assessing the presence and extent of specific necroinflammatory changes and 
fibrosis, however, firm recommendations of when to perform a liver biopsy in 
routine clinical setting have not yet been developed and care will continue to 
require individualization. A pragmatic approach in younger patients without 
clinical evidence of more advanced disease in a trial period of increase exercise 
and improved dietary habits .(33) The role of baseline or serial biopsy in patients 
with liver abnormalities while using statin drugs has yet to be established. The 
use of surrogate markers such as aminotransferases and fibrosis markers may 
have a limited role in pilot study, but are not adequate end point for definitive 
investigations (34) . 
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1.2.7.6 Prognosis of NAFLD: 
 
    Prognosis in NAFLD is being defined as follows, patients with pure 
steatosis on liver biopsy seem to have the best prognosis within the spectrum 
of NAFLD (35) , whereas feature of steatohepatitis or more advance fibrosis 
are associated with a worse prognosis. In one study, progression of liver 
fibrosis occurred only in patients with necroinflammation on liver biopsy(36) 
There was a trend for more liver related deaths among patients with NASH 
than those without NASH, although the significantly greater proportion of 
patients can also explain this difference with cirrhosis among those with 
NASH(37). 
  
1.2.7.7 Treatment of Type 2 DM & NAFLD: 
 
    There are two main aims of therapy for diabetics, first to relieve symptoms 
and to prevent the long-term complications. Treatment of NAFLD is aiming 
for modification of the risk factor conditions. Both treatments included 
- Good glycemic control, this can be tested by glucosylated hemoglobin      
(Hb AlC). Hemoglobin is formed in new red blood cells, which enter the 
circulation without any glucose attached. However, red cells are freely 
permeable to glucose, as a result glucose becomes irreversibly attached to 
Hb at rate dependent upon the prevailing blood glucose. A strong correlation 
was noted, such that a HB A1C value of 7 percent represented a mean blood 
glucose value of about 150 mg/dl (8.3mmol/L), and HB A I C of 9 percent 
represent a mean blood glucose value of about 210 mg/dl (11.7mmol/L), the 
HBA1C is seven percent (38) . 
 
 
 13 
1.2.7.7.1   Drugs:-  
 
              Insulin resistance seems to be the common denominator in NAFLD. 
There are two classes of drugs that have been shown to correct insulin 
resistance.  
              Biguanides metformin primarily by decreasing hepatic glucose 
production both in the fasting and postprandial state and by decreasing insulin 
in the muscle cell through an increase in the activity of the glucose transporters. 
This lowers both fasting and postprandial serum glucose levels.  Additional 
positive effects of  metformin include lowering of triglyceride , total cholesterol 
and raising the HDL (39). 
       In one study, metformin was found to improve the serum aminotransferase 
activities, however, no histological data were provided  (40) . 
         Thiazolidinediones are drugs that act via peroxisome proliferation 
activated receptor and  improve insulin sensitivity. 
         Lipid lowering Agents:-  
            Clofibrate has beneficial effect on liver function and hepatic histology, 
Gemfibrozil improve the liver chemistry , but hypertriglyceridemia is often 
associated with NAFLD(41) . Other drugs that protect hepatocytes , include 
UDCA , Betaine, Vitamin E, lecithin and B- Carorene.   
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OBJECTIVES 
 
    The aims of this work are: 
• To determine the prevalence of fatty liver disease in type 2 diabetic 
Sudanese patients 
• To study the risk factors associated with development of fatty liver in type 
II diabetic patients. 
• To study  complications of diabetes among those with fatty liver. 
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PATIENTS AND METHODS 
 
    This is a descriptive cross sectional study in Sudanese patients with Type 2 
diabetic patients of all age group, both sexes, who had no underlying liver disease 
and or history of alcohol consumption. 
Study population  
A  Sample size of 50 patients was collected from January 2004 to July 2004. The 
entire sample had an abdominal ultrasound examination; the same radiologist did 
radiological examination for all patients. 
Place of the study 
National Center of Gastrointestinal and Liver Disease(Ibn Sina Hospital) in 
Khartoum & Health insurance clinic in Khartoum North. 
Data sources 
Information obtained by the investigator through history and examination of 
patients. 
Data collection 
   Data will be collected by a self -adminstered questionnaire. This was constructed 
in sections to address different aspect of the study as follows: 
• Personal data 
• Presentation 
• Physical examination 
• Investigations 
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The patients will be subjected to following investigations:- 
- Full liver function tests including liver enzymes and prothrombin time. 
- Fasting triglyceride. 
- Fasting Blood Glucose. 
- Hb AlC or serial of fasting Blood Glucose. 
- HCV and HBV screening test. 
- Abd ultrasound. 
- Liver biopsy (if the diagnosis is unclear). 
- Gastro copy if indicated. 
Data analysis 
All the collected data were entered in a master sheet and analyzed by SPSS 
computer system. The results expressed in numbers and percentages. 
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RESULTS 
 
         This study included 50 patients with type II diabetes. Screening for fatty liver 
by abdominal ultrasound and other relevant blood tests were performed. 
• In the study group 26 (52%) of patients were female with male to  
     female ratio (0.8: 1)( Fig. 1) 
• The age of patients on presentation ranged from 40 to 85 with  
      mean age of 65 ±15.7 SD (Fig.2) 
• Figure 3 shows the geographical distribution of all patients (n = 50); 
34(68%) of all patients were from northern states of Sudan.  
• Figure 4 shows the socioeconomic status of the patients in the studied group. 
• Thirty-eight (76%) patients have fatty liver disease with male to  
      female ratio (1:1.7) (Fig.5) 
• Thirsty-three (87%) patients were symptomatic and 17 (13%)  
     were a symptomatic (Fig.6). 
• In the study group the main presenting symptoms were upper      
     abdominal pain (52%) fatigability (38%) hepatomegaly (6%)         
     Jaundice (1%) (n = 38) other (3%)  (Fig. 7). 
• Table 1 shows Co- morbidities for fatty liver disease in the study                        
      group. 
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• Thirty –eight (100%) of the patients with FLD used combination therapy for            
their diabetes( Table. 2) 
• In the study group 20 (53%) of patients were over weight, 10 (26%) had 
normal BMI, 7(18%) were obese, while 1 (3%) were morbidly obese (Fig. 8) 
• In the study group, the WHR for female was more than 0.85 in 20 (53%) of 
female patients with FLDand (38%) in patients with normal liver, while for 
male it was more than 0.90 in 5 (13%) of patients with FLD and 5 patients 
with normal liver (n = 38) ( Table .3). 
• Hepatomegally was clinically detected in 14 (39%) of patients the rest of the 
presenting features are shown in (Fig. 9). 
• Figure 10 shows diabetic complication among the studied group in patients 
with FLD 34(89%) had retinopathy, 23(61%) had peripheral neuropathy and 
10 (27%) had other complications while in those with normal liver 
7(57%),5(45%) 2(21%) had the same complications respectively.  
• Thirsty (79%) of patients with FLD had a serum albumin level of ≥ 3.5g/dl, 
while 8 (21%) of patients had serum albumin level of ≤ 3.5g/dl  (Fig. 11). 
• In the study group AST/ALT ratio were more than one 21(55%) of patients 
while ≤ one in 17(45%) of patients FLD( Table .4). 
• Thirty –two (84%) of patients FLD had INR ≤ one, 6(16%) of patients had 
INR ≥ one (Fig. 12) 
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• Serum bilirubin level ≤ 1mg/dl were found in 35 (92%) of patients FLD and 
≥ 1mg/dl in 3(8%) of patients (Fig.13). 
• In the study group 28 (74%) of patients FLD had fasting blood glucose ≥ 
126mg/dl, while 10(26%) of patients had FBG ≤ 126 mg/dl while those with 
normal liver had (33%) FBG level more than 126 mg/dl and (67%) of them 
had FBG level less than 126mg/dl. (Fig.14). 
• Figure 15 shows glycosylated haemoglobin presentages in the study group  
• In the study group 24 (63%) of patients had a fasting triglyceride level ≥ 200 
mg/dl while 14(37%) of patients had F.T. level ≤ 200mg/dl.All patients with 
normal liver had a serum triglyceride (Table 5)  (n = 38) . 
• HCV and HBV screening tests were performed to all patients and negative 
results for both viruses were obtained. 
Serum gamma glutamyl transpeptidase were requested for all patients only 5 of 
them did the test. Their results were with the normal range. 
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Table 1 : Co- 
morbidities in the study group  
 
 
 
 
 
 
 
 
FLD Normal liver 
Co- morbidities No % No % 
Obesity 8 21 3 25 
Hypertesion 20 53 8 67 
Ischemic heart disease 13 34 9 75 
Family History as: 
• Diabelis 
• Hyperlipidemia 
• Obesity 
 
32 
3 
10 
 
84 
7 
26 
 
12 
0 
7 
 
100 
0 
58 
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Table 2 : The hypoglycemic drugs used by  the study group as monotherapy 
or combined (n=50) 
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       Table 3 : WHR for females and males in the study group with FLD (n=38) 
 
         F ≤ 0.85                M ≤ 0.90   
             F = 24 patients       male = 14 
 
 
 
 
Drug 
 
No 
 
% 
 
Insulin 
 
8 
 
21 
 
Glibenclamide 
 
20 
 
53 
 
Metformin 
 
13 
 
34 
 38 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: AST/ALT Ratio in the study group with FLD(n=38) 
 
 
AST/ALT Ratio 
 
 
 
FLD Normal liver 
WHR No % No % 
 
Females 
 
≤ 0.85 
≥0.85 
 
 
4 
20 
 
17 
83 
 
1 
1 
 
4 
4 
 
Males 
 
≤ 0.90 
≥ 0.90 
 
9 
5 
 
64 
36 
 
5 
5 
 
38 
38 
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Ratio 
 
No 
 
% 
 
≥ 1 
 
21 
 
55 
 
≤ 1 
 
17 
 
45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Fasting triglyceride level among the study group (n=50)  
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FLD 
 
Normal liver 
 
Fasting Triglyceride level 
 
No 
 
% 
 
 
No 
 
% 
 
 
≤ 200 mg/dl 
 
≥ 200 mg/dl 
 
14 
 
24 
 
37 
 
36 
 
12 
 
0 
 
100 
 
0 
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DISCUSSIO 
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The current data represent an attempt to clinically, biochemically and 
radiological estimation of the prevalence of fatty liver in Sudanese patients with 
type II diabetes.  
The study population consisted a cross sectional study in 50 patients with 
type II diabetes for more the 10 years and had no history of alcohol consumption or 
chronic liver disease. 
Using ultrasonography as a tool for screening we find two third (76%) of the 
study group have fatty liver. The result is similar or near to what obtained by 
Gevin(25). 
Females to male ratio 1.7 : 1 which seems to be equal and this is may be due 
to the sample size which is 50. Moreover, most series characterized a NAFLD 
patient as a middle-aged woman, but other have shown a significantly greater 
prevalence of NAFLD in males than females(20). 
The mean age for all patients ± SD was 65 ± 15 – 7 years. According to the 
classifications of diabetes, type II occurs commonly in middle age(1). 
Most of the study group had no or sedentary jobs and limited income for this 
reasons they attended in the health insurance clinics where cases are selected. 
FLD appears to be more common in patients (68%) originally from northern 
Sudan. 
In this study the majority of patients are asymptomatic (87%), this similar to 
a result obtained in quadrennial review of non alcoholic fatty liver disease(20). 
The main presenting symptoms are upper abdominal pain and fatigability.  
The commonest co-morbidities in patients with FLD were hypertension in (53%), 
ischaemic heart disease in (34%), obesity in (21%) and family history of diabetes 
(84%).  
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These result are similar to those reported by Gevin(25) , were (30%) of type II 
diabetic patients and (25%) of obese and (52%) of those with hypertension was 
found to have FLD in routine follow-up. 
Considering waist – hip – ratio as a part of physicals examination in this 
study, results showed that it is increased in (53%) of females patients with FLD, 
(38%) in those female with normal liver. And the ratio increased in (13%) in males 
with FLD and also in those with normal, although there is no difference in the two 
male groups in the measurement of central obesity but still the result should be 
considered. Because central obesity occurs with diabetes in the context of      
syndrome X . Which is a cluster of metabolic abnormalities that present coronary 
heart disease risk, occurring in an individual more than often than can be expected 
by chance. 
Microvascular complication namely retinopathy and peripheral neuropathy 
were found in (89%), (61%) respectively in patients with FLD and (57%), (44%) 
respectively in those with normal liver. These result seems to be high in diabetic 
patient with FLD, which could be explained by the fact that all diabetic patients 
have the disease for more than 10 year when complications started to occur. The 
second explanation that hepatic injury in diabetes may often goes paralleles with 
diabetic microangiopathy(13,25).Macrovascular complications appear to be 
uncommon among our patients. 
As expected liver profile included serum amino transferases levels, serum 
albumin level, and serum bilirubin levels were normal or near normal. 
Prothrombine time also within the normal range this similar to what found in 
report of Mezey; that FLD can be associated with normal or mild abnormality in 
serum amino tranferase and alkaline phosphatase(25).  
High fasting blood glucose levels was found in (74%) of patients with FLD. 
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As a predictor for glycemic control, glycosylated haemoglobin percentages 
of more than (7%) was found in (84%) of patients with FLD, which may indicate a 
relation between glycemic control and the presence of fatty liver. 
High fasting triglyceride levels were found in (63%) of patients with FLD 
while the others had normal or low levels. In one study by Zettetman(27) in type II 
diabetes patients 50% - 75% of patients of those who had FLD between 20% - 80% 
of them had hyperlipidemia. Also other report by Estenban found that FLD is 
found in more than (50%) of obese with long standing diabetes and 
hypertriglycerdemia. This may be due to metabolic disturbance which occurs in 
diabetes.  
HBV and HCV screening test was requested as exclusion criteria for other causes 
of fatty liver disease.                     
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CONCLUSION 
 
• Fatty liver disease, as determined by ultrasound, is common in 
Sudanese patients with type 2 diabetes and most of the cases are 
females. 
 
• Poor glycemic control, hyperlipidemia  and central obesity were 
associated with fatty liver. 
• Diabetic complications were commoner in those with fatty liver. 
 
• Ultrasound is a good test for detecting fatty liver. 
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RECOMMENDATIONS 
 
• Fatty liver disease is attracting increasing significance. Future 
work is required to elaborate in the pathogenesis of this condition, 
risk factors, long term complications and develop effective 
management. 
 
• Physicians should actively check for the presence of fatty liver in 
those who are diabetic with central obesity and poor glycemic 
control 
 
• Increase awareness of high risk group of patients like diabetic, 
obese  and  hypertensive, a bout the disease, risk factors, 
management and prognosis. 
 
• Treatment is promising, but conservative methods are largely used. 
Weight reduction and good control for blood glucose and lipids 
should be achieved. 
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Questionnaire 
The prevalence of Fatty liver in Sudanese patients 
with type II diabetes  
 
        Name:------------------------              Serial No---------------------------- 
        Age----------------------------             Sex ------------------------------------ 
       Occupation--------------------            Residence------------------------------ 
       Origin.-------------------------            Tribe------------------------------------ 
       Tel No--------------------------           Duration of DM-----------------------  
      Asymptomatic 
     Symptomatic:      
                 Fatigue                                    Rt upper abd. Discomfort 
                 Hepatomegally                        Jaundic 
                Other---------------------------------------------------------------------- 
  Co. morbid conditions:- 
   Hyperlipidemia                 HT                   IHD                           Obesity 
   Diabetic complication: 
   Specify:------------------------------------------------------------------------------- 
  FH:- 
                   DM                     HT                                    Obesity 
 
                  Other------------------------------------------------------------------------ 
    SH: Social status: ------------------------------------------------------------------- 
   Smoking 
   DH: 
 
   Insulin 
 
   Daonil 
 
   Metformin 
 
  Others:------------------------------------------------------------------------------ 
 O/E: 
        Wt--------------            Ht---------------------               BMI---------------- 
        Non obese               obese               Over weight                Morbid obesity 
 
                                                                                    Waist/hip: Ratio-------------- 
              
         Pallor                      Jaundice 
        
      Arcus senilis            Xanthoma           CVS             
                           
                        Xanthellasma                                          Chest 
 
       Palpable liver                                                     Liver span-------------------CM 
      Palpable spleen 
     Ascites                                                  L.L.oedema 
     NS: 
- Fundus diabetic retinopathy 
- Peripheral neuropathy 
 
 
Investigations: 
Liver function test: 
- ALT----------------------------------- 
- AST----------------------------------- 
- AST/ALT ratio---------------------- 
- Gamma GT 
- S. albumin-------------------------- 
- S. Bilirubin------------------------- 
- Prothrombine time---------------- 
- Fasting blood Glucose-------------------- 
- Hb A1Cor serial blood glucose 
- Fasting triglyceride----------------------------- 
- HCV--------------------------------------------- 
- HBV------------------------------------------ 
- ECG---------------------------------------------- 
Abd/U/S: 
Liver Appearance: 
Bright-------------------- 
Degree of infiltration: 
- Focal--------------------------------- 
- Diffuse--------------------------------- 
- Size--------------------------------------- 
- PV-------------------------------------- 
- SV------------------------------------------ 
- Cl---------------------------------------------- 
- Pancrease------------------------------------- 
- Spleen------------------------------------------ 
- Ascites---------------------------------------- 
Liver biopsy----------------------------------------------------------- 
                   ------------------------------------------------------------ 
- Gastroscopy--------------------------------------------------- 
 
